Effect of Cost-Exemption Policy on Treatment Interruption in Patients with Newly Diagnosed Pulmonary Tuberculosis in South Korea
International Journal of Health Policy and Management · 2024
DOI: 10.34172/ijhpm.8262 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Health Policy and Management, 2024. Verfasst von Sang Chul Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology and Allergy, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea. Hauptthemen laut MEDLINE: Tuberculosis, Pulmonary, Antitubercular Agents. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
In 2021, South Korea had the highest incidence rate (49 per 100,000 population) and the third highest mortality rate (3.8 per 100,000 population) due to pulmonary tuberculosis (TB) among Organization for Economic Co-operation and Development countries. Notably, premature interruption of TB treatment interferes with TB control efforts. Therefore, we examined the effect of the co-payment waiver on treatment interruption and mortality among patients with pulmonary tuberculosis in South Korea.
Methods
Patients who had newly treated TB in South Korea from 2013 to 2019 were selected from the nationwide data of the entire Korean National Health Insurance Service population. The effects of policy implementation on treatment adherence and mortality rates depending on treatment interruption history were evaluated.
Results
In total, 73,116 and 1,673 patients with drug-susceptible (DS) and multidrug-resistant (MDR) pulmonary TB, respectively, were included in the final study population. After implementing the cost-exemption policy, the treatment interruption rate tended to decrease in the continuation phase in the DS-TB group (slope change: −0.097, P=0.011). However, it increased in the intensive phase in the MDR-TB group (slope change: 0.733, P=0.001). MDR-TB patients were likely to experience an interruption of TB treatment (adjusted odds ratio, 6.04; 95% confidence interval [CI], 5.43–6.71), and treatment interruption history was a significant risk factor for 1-year and overall mortality rates (adjusted hazard ratios: 2.01, 95%CI, 1.86–2.18 and 1.77, 95%CI, 1.70– 1.84, respectively) in the DS-TB group.
Conclusion
Implementing the cost-exemption policy effectively reduced the treatment interruption rate among patients with DS pulmonary TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonology and Allergy, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.
- Department of Research and Analysis, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.
ORCID-Profile: Sang Chul Lee, Jae Kwang Lee, Hyun Woo Ji, Jung Mo Lee, Seon Cheol Park, Chang Hoon Han
Zitieren
APA
Lee, S. C., Lee, J. K., Ji, H. W., Lee, J. M., Park, S. C., & Han, C. H. (2024). Effect of Cost-Exemption Policy on Treatment Interruption in Patients with Newly Diagnosed Pulmonary Tuberculosis in South Korea. International Journal of Health Policy and Management. https://doi.org/10.34172/ijhpm.8262
Vancouver
Lee SC, Lee JK, Ji HW, Lee JM, Park SC, Han CH. Effect of Cost-Exemption Policy on Treatment Interruption in Patients with Newly Diagnosed Pulmonary Tuberculosis in South Korea. International Journal of Health Policy and Management. 2024. doi:10.34172/ijhpm.8262
BibTeX
@article{Lee2024,
author = {Lee, Sang Chul and Lee, Jae Kwang and Ji, Hyun Woo and Lee, Jung Mo and Park, Seon Cheol and Han, Chang Hoon},
title = {Effect of Cost-Exemption Policy on Treatment Interruption in Patients with Newly Diagnosed Pulmonary Tuberculosis in South Korea},
journal = {International Journal of Health Policy and Management},
year = {2024},
doi = {10.34172/ijhpm.8262}
}
EUVIMED